ArticleMicrobiology spectrum2026
tRNA-derived small RNA, tsRNA-5017b, as a novel biomarker for predicting severity in severe fever with thrombocytopenia syndrome.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
tRNA-derived small RNAs (tsRNAs) represent a novel class of highly conserved non-coding RNAs that play crucial roles in various cellular processes, including cell proliferation and the initiation of viral reverse transcription. Despite their significant biological functions, studies exploring the role of tsRNAs in infectious diseases remain limited. Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne hemorrhagic fever caused by SFTS virus (SFTSV), which is associated with a high fatality rate. This study investigates the potential diagnostic value of serum tsRNAs in SFTS. Using tsRNA sequencing, we analyzed the differential expression of serum tsRNAs between SFTS patients and healthy controls, followed by validation using quantitative real-time PCR (qRT-PCR) in individual samples. Our findings revealed that the expression levels of tsRNA-3002a, tsRNA-5007a, tsRNA-5013c, tsRNA-5017b, tsRNA-5027b, and tsRNA-5030c were significantly altered in the serum of SFTS patients compared to healthy controls. Among these, tsRNA-5017b showed the most pronounced upregulation, with its expression progressively increasing in parallel with the severity of the disease. Further analysis demonstrated that tsRNA-5017b alone could predict SFTS severity at admission with a specificity of 93%. When combined with conventional laboratory markers such as platelet count (PLT) and aspartate aminotransferase (AST), the sensitivity reached 91.7%. Bioinformatics analysis suggested that tsRNA-5017b may be involved in the regulation of immune responses, apoptosis, and inflammatory pathways. In conclusion, this study is the first to identify the expression of tsRNA in the serum of SFTS patients and proposes tsRNA-5017b as a promising biomarker for predicting disease severity at admission. IMPORTANCE: Severe fever with thrombocytopenia syndrome (SFTS) is a fatal tick-borne disease caused by severe fever with thrombocytopenia syndrome virus (SFTSV), with limited early diagnostic tools available. This study identifies serum tRNA-derived small RNAs (tsRNAs) as potential biomarkers for SFTS, revealing that tsRNA-5017b, in particular, correlates with disease severity. Our findings show that tsRNA-5017b is associated with SFTS severity at admission, with high specificity alone and improved sensitivity when combined with conventional markers. This research highlights the potential of tsRNA-based biomarkers in diagnosing and assessing disease severity in SFTS, advancing our understanding of viral pathogenesis and immune regulation in infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.